Phase II trial of bintrafusp alfa in patients with metastatic MSI-H cancers following progression on immunotherapy.

Van K. Morris,Michael Lam,Xuemei Wang,Michael J. Overman,Benny Johnson,Bryan K. Kee,Robert A. Wolff,Arvind Dasari,Isabel R. Zorrilla,Alda L. Tam,Dipen M. Maru,Scott Kopetz

Phase II trial of bintrafusp alfa in patients with metastatic MSI-H cancers following progression on immunotherapy.

2021

Van K. Morris
Michael Lam
Xuemei Wang
Michael J. Overman
Benny Johnson
Bryan K. Kee
Robert A. Wolff
Arvind Dasari
Isabel R. Zorrilla
Alda L. Tam
Dipen M. Maru
Scott Kopetz

79Background: Microsatellite instability-high (MSI-H) tumors are characterized by deficient mismatch repair, high tumor mutation burden, and exceptional anti-tumor responses to immunotherapy. While...

Keywords:

DNA mismatch repair
in patient
Immunotherapy
Microsatellite
Mutation
Cancer research
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations